Ovarian Cancer Clinical Trials

153 studies are recruiting for ovarian cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

   This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, La Jolla, California

   Locations

   5 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07216105 on ClinicalTrials.gov

2. Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

   The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Cal, Los Angeles, California

   Locations

   8 in total

   Run by

   Tubulis GmbH

   See if you can join NCT07736937 on ClinicalTrials.gov

3. Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers

   The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approx…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UW Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT07125209 on ClinicalTrials.gov

4. Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

   To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05636111 on ClinicalTrials.gov

5. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Denver, Colorado

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

6. Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

   This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cispla…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT06040970 on ClinicalTrials.gov

7. Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

   The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of X…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Xencor Investigative Site, Lake Success, New York

   Locations

   4 in total

   Run by

   Xencor, Inc.

   See if you can join NCT07593092 on ClinicalTrials.gov

8. A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

   This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Site 0104, Beverly Hills, California

   Locations

   59 in total

   Run by

   K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

   See if you can join NCT07546500 on ClinicalTrials.gov

9. Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

   The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In this study, an investiga…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Broward Health, Fort Lauderdale, Florida

   Locations

   4 in total

   Run by

   University of Miami

   See if you can join NCT06412120 on ClinicalTrials.gov

10. IDOV-Immune for Advanced Solid Tumors

    This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    5 in total

    Run by

    ViroMissile, Inc.

    See if you can join NCT06910657 on ClinicalTrials.gov

11. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

    HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Arkansas, Little Rock, Arkansas

    Locations

    12 in total

    Run by

    Whitehawk Therapeutics, Inc.

    See if you can join NCT07444814 on ClinicalTrials.gov

12. Clinical Pre-screening Protocol for Ovarian Cancer

    The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Th…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    9 in total

    Run by

    Allarity Therapeutics

    See if you can join NCT03877796 on ClinicalTrials.gov

13. The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons

    BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. Also, this cancer is becoming more common and deadly for black women than white women. Researchers want to find better ways to take …

    Stage

    Not phased

    Ages

    18 to 99

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT03538665 on ClinicalTrials.gov

14. Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer

    To provide a comprehensive yoga therapy (CYT) program to patients with ovarian, fallopian tube, or primary peritoneal cancer who are scheduled to receive chemotherapy and then undergo surgery. Researchers want to learn about the effects of the program on patients' quality of life and other outcomes…

    Stage

    Not phased

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06545604 on ClinicalTrials.gov

15. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #108, Goodyear, Arizona

    Locations

    18 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

16. Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

    This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Chicago Medical Center, Chicago, Illinois

    Locations

    6 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT04918186 on ClinicalTrials.gov

17. Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer

    An anticipated 200 women with newly diagnosed ovarian and endometrial cancer scheduled to receive chemotherapy (adjuvant chemotherapy after surgery or neoadjuvant chemotherapy before surgery) will be recruited from Smilow Cancer Hospital Network at Yale Cancer Center (YCC) and Sylvester Comprehensi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Yale University, New Haven, Connecticut

    Locations

    2 in total

    Run by

    Yale University

    See if you can join NCT05761561 on ClinicalTrials.gov

18. Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

    This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether N…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT04520139 on ClinicalTrials.gov

19. Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

    This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT07064018 on ClinicalTrials.gov

20. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    004, Birmingham, Alabama

    Locations

    49 in total

    Run by

    Corcept Therapeutics

    See if you can join NCT06906341 on ClinicalTrials.gov

21. The Better, Harder, Faster, Stronger Study

    The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.

    Stage

    Not phased

    Ages

    55 and older

    Site

    Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT07220512 on ClinicalTrials.gov

22. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rec…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham Womens & Infants Center, Birmingham, Alabama

    Locations

    9 in total

    Run by

    University of Alabama at Birmingham

    See if you can join NCT04606914 on ClinicalTrials.gov

23. Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

    This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study part…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Phoenix, Arizona

    Locations

    11 in total

    Run by

    NX Development Corp

    See if you can join NCT05804370 on ClinicalTrials.gov

24. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

    This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole bra…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06580002 on ClinicalTrials.gov

25. Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is no…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    University of Florida, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT05000294 on ClinicalTrials.gov